Literature DB >> 24755685

The diagnostic importance of matrix metalloproteinase-7 and nestin in gastrointestinal stromal tumors.

Kemal Peker1, Ilyas Sayar2, Ibrahim Gelincik3, Gülay Bulut4, Tuba Dilay Kökenek Ünal5, Serkan Şenol6, Aysun Gökçe7, Arda Isik1.   

Abstract

BACKGROUND: The importance of the matrix metalloproteinase-7 (MMP-7) and nestin immunomarkers, C-kit proto-oncogene (CD117), and the efficiency of the Ki-67 proliferation index for gastrointestinal stromal tumors were evaluated.
MATERIAL AND METHODS: This study was conducted by examining the microscope slides of 72 patients with gastrointestinal stromal tumors that were sent to the pathology laboratory between 2007 and 2012. Immunohistochemical staining for CD117, MMP-7, nestin, and marker of proliferation Ki-67 was performed. The correlations between the positive results for Ki-67, CD117, MMP-7, and nestin were evaluated relative to the tumor characteristics of size, localization, grade, cellular type, cellularity, cytology type, growth pattern, ulceration, necrosis, hemorrhage, invasion depth, and lymph node metastasis.
RESULTS: The tumor was localized in the stomach in 42 of the patients, the intestines in 19, the colon in 7, and the rectum in 4. Comparisons among the groups showed that MMP-7 was correlated with the tumor grade (p<0.001), cellularity (p<0.009), cytologic atypia (p<0.001), ulceration (p=0.002), necrosis (p<0.001), and tumor size (p=0.001). Nestin was correlated with the tumor grade (p=0.013), and tumor size (p=0.024). Correlations among CD117, MMP-7, nestin, and Ki-67 were examined. Nestin and Ki-67 were both significantly correlated with CD117 and MMP-7 [(r=0.279, p=0.018), (r=0.322, p=0.006), (r=0.386, p=0.001), (r=0.386, p=0.002)], respectively.
CONCLUSIONS: MMP-7 and nestin may be beneficial as markers, given their sensitivity to gastrointestinal stromal tumors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24755685      PMCID: PMC4005864          DOI: 10.12659/MSM.890303

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


Background

Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors with specific histological characteristics that are primarily localized in the gastrointestinal system and abdomen. Normally, interstitial Cajal cells, which regulate peristalsis in the gastrointestinal system, are found in and around the myenteric plexus of the intestinal wall. It is thought that GISTs are mesenchymal tumors originating from Cajal cell precursors [1] and that a mutation in the C-kit proto-oncogene (CD117) protein found in the Cajal cells plays a role in the pathogenesis of the GISTs. In some of these tumors, a mutation in the platelet-derived growth factor receptor alpha gene, another tyrosine kinase proto-oncogene, is seen instead of the C-kit mutation, but in others, no mutation is detected [2-4]. CD117 acts as a receptor for growth and stem cell factors, and the receptor-ligand relationship between these factors and C-kit activates internal tyrosine kinase, which is followed by the phosphorylation of intracellular proteins and the activation of cell signaling pathways. These series of events are important in regulating the proliferation, apoptosis, adhesion, and differentiation in many cell types, including the interstitial Cajal cells [5]. While C-kit activation is sufficient for interstitial Cajal cell hyperplasia, additional oncogenic events are required for actual neoplastic GIST formation [3]. Since omental and mesenteric primary stromal tumors display the typical immunohistochemical profile of GISTs, and since interstitial Cajal cells are not found in this location, it is believed that GIST may develop from multipotent mesenchymal stem cells (interstitial mesenchymal precursors) [6]. Matrix metalloproteinases (MMPs) are calcium-dependent endopeptides containing zinc, which are involved in the disruption of the extracellular matrix and remodeling of the tissue. The MMPs provide hemostasis by increasing in normal tissue at the physiological state [7]. Nestin is an intermediate filament protein that is responsible for the rapid division of progenitor cells during tissue renewal and development [8]. The labile marker of proliferation Ki-67 is a non-histone nuclear protein that is closely related to the cell cycle and growth, the mid-G1, S, and G2 phases of the cell cycle, and mitosis [9]. Currently, the most valid immunohistochemical method for diagnosing GISTs is the demonstration of the C-kit mutation in CD117 [10]. In our study, we examined the expression of the MMP-7 and nestin immunomarkers and CD117, and evaluated the efficiency of the Ki-67 proliferation index.

Material and Methods

This study was conducted using the microscope slides of 72 patients (range 30–81 years; mean age 58.55±10.59 years) with GISTs that were sent to the pathology laboratory between 2007 and 2012. We obtained these slides from the archives and re-evaluated them via light microscopy. Appropriate blocks were then selected for immunohistochemical staining for CD117 (Product code: NCL; dilution ratio: 1/40), MMP-7 (Product code: ab38996; dilution ratio: 1/150), nestin (Product code: ab93666; dilution ratio: 1/200), and Ki-67 (Product code: NCL-MM1; dilution ratio: 1/150). Sections were prepared from the blocks and stained using a fully automated immunohistochemistry (IHC) device. After staining, the CD117, MMP-7, and nestin were scored as +, ++, or +++ based on the cytoplasmic and membranous staining patterns and intensity [11-13]. The statistical comparison of the positive distribution of the CD117, MMP-7, and nestin values were divided into two groups, one composed of the negative and +1 values, and the other of the +2 or more values. The Ki-67 proliferation index rates were calculated by determining the total number of cells and the number of positive cells that displayed nuclear staining in 3 randomly selected 40× high-magnification areas. This index was scored by assigning a value of + for ≤1%, ++ for 1–10%, and +++ for >10%. In addition, + represented a tumor size of <5 cm, ++ represented a tumor between 5 and 10 cm, and +++ indicated a tumor of ≥10 cm. The depth of invasion was categorized as mucosal, submucosal, muscular, or serosal, and the growth pattern was identified as either expansive or infiltrative. Furthermore, the cell type was classified as fusiform, epithelioid, or mixed. Ulceration, necrosis, and bleeding were also noted as being either present or absent, and the tumor grade was classified as belonging to the low (L), intermediate (IM), or high (H) risk groups according to the risk categorization table prepared by Fletcher et al. [11] that was based on tumor diameter and number of mitoses.

Statistical analysis

Mann Whitney U tests and one-way ANOVAs were used to compare the ages of the patients between groups based on the assumed parametric distribution. Ages are presented as the mean ± standard deviation. Categorical variables were compared by Pearson, Yates, or Fisher chi-square tests and are presented as a count and percentage. Spearman correlation coefficients were used to determine the correlations between CD117, MMP-7, nestin, Ki-67 and the other parameters. The sensitivity and specificity of MMP-7 and nestin were calculated to compare their diagnostic performance to CD117 as the criterion standard. The IBM SPSS Statistics 20 (SPSS Inc., IBM Corporation, Armonk, NY, USA) and MedCalc 12.7.8 (MedCalc Software, Ostend, Belgium) programs were used to perform the analyses, and a p-value <0.05 was considered significant.

Results

The tumor was localized in the stomach in 42 of the patients (58.3%), the intestines in 19 patients (26.4%), the colon in 7 patients (9.7%), and the rectum in 4 patients (5.6%). Of the 3 risk groups, 28 (38.9%) patients were in the L risk group, 23 (31.9%) were in the IM risk group, and 21 (29.2%) were in the H risk group. The tumor was <5 cm in 33 of the patients (45.8%), 5–10 cm in 24 patients (33.3%), and >10 cm in 15 patients (20.8%). Four of the cases included epithelioid cells (5.6%), while 49 had fusiform cells (68.1%) and 19 contained mixed-type cells (26.4%). We also determined that cellularity was present in 53 cases (73.6%) and absent in the other 19 (26.4%). In addition, both ulceration and necrosis were present in 22 cases (30.5%), but absent in 50 (69.5%). Furthermore, we found that hemorrhage was present in 37 cases (51.4%) and absent in 35 (48.6%), whereas cytologic atypia was present in 19 cases (26.4%), mild in 39 cases (54.2%), and absent in 14 cases (19.4%). Seventeen (23.6%) of the GISTs were located in the submucosa, 19 (26.4%) were found in the muscle layer, and 36 (50%) appeared to have extended to the serosa. We also found that 63 (86.1%) of the cases were expansive, while only 10 (13.9%) were infiltrative. For the immunohistochemical staining with CD117, 13 (18.1%) of the 72 cases were classified as +, 6 (8.3%) as ++, and 51 (70.8%) as +++, while 2 (2.8%) were negative for CD117 staining. In the L risk group, no staining was seen in 1 of the 28 samples (3.5%), 7 (25%) were classified as +, 2 (7%) as ++, and 18 (64.5%) as +++. In the 23 cases in the IM risk group, 1 (4.4%) tested negative, while 5 (21.7%) showed + staining, 4 (17.4%) had ++ staining, and 13 (56.5%) had +++ staining. Lastly, in the 21 samples in the H risk group, 1 (4.8%) had + staining and 20 (95.2%) showed +++ staining (Figure 1). Correlations of CD117 with the other groups (nestin, MMP7, and Ki 67) showed that the parameters of localization, and grade were statistically significant. However, no significant correlations were found between CD117 positivity and tumor size, cellularity, cytologic atypia, ulceration, necrosis, hemorrhage, or invasion depth.
Figure 1

+++ Cytoplasmic and membranous staining with CD117 in high-risk GISTs (immunoperoxidase ×200).

With regard to the immunohistochemical staining for MMP-7, 5 (6.9%) of the 72 cases were categorized as +, 29 (40.3%) as ++, and 37 (51.4%) as +++. One (1.4%) of the samples in this group was negative. In the 28 cases in the L risk group, 1 (3.5%) showed no staining, 2 (7%) had + staining, 19 (68%) indicated ++ staining, and 6 (21.5%) showed +++ staining. For the 23 cases in the IM risk group, 1 (4.4%) had + staining, 9 (39.1%) had ++ staining, and 13 (56.5%) had +++ staining. In the H risk group, which consisted of 21 cases, 2 (9.5%) were classified as +, 1 (4.8%) as ++, and 18 (85.7%) as +++ (Figure 2).
Figure 2

+++ Cytoplasmic and membranous staining with MMP7 in high-risk GISTs (immunoperoxidase ×200).

When testing for nestin, we found that 3 (4.1%) of the 72 cases showed + staining, 4 (5.6%) showed ++ staining, and 63 (87.5%) had +++ staining. Two (2.8%) of the cases were negative for nestin. Of the 28 L risk group samples, 1 (3.5%) was negative, 2 (7%) showed + staining, 3 (10.5%) had ++ staining, and 22 (79%) had +++ staining. Of the 23 cases in the IM risk group, 1 (4.4%) was negative, 1 (4.4%) showed + staining, 1 (4.4%) had ++ staining, and 20 (86.8%) showed +++ staining. Finally, in the 21 cases in the H risk group, all of the samples (100%) were categorized as +++ (Figure 3). There were no statistically significant differences for patients’ characteristics. For Ki-67, there were statistically significant differences for the localization, grade, cellularity, cytologic atypia, necrosis, hemorrhage, invasion depth, and tumor size, but not with the other patient characteristics (Table 1; Figure 4).
Figure 3

+++ Cytoplasmic and membranous staining with nestin in high-risk GISTs (immunoperoxidase ×200).

Table 1

Comparison results of the patient characteristics among subgroups of the Ki-67.

Ki-67 (%)p
<1 (n=37)1–10 (n=19)>10 (n=16)
LocalizationStomach26 (61.9)12 (28.6)4 (9.5)0.012b
Intestines9 (47.4)4 (21.1)6 (31.6)
Colon1 (14.3)1 (14.3)5 (71.4)
Rectum1 (25)2 (50)1 (25)
GradeLow risk26 (92.9)2 (7.1)0<0.001a,b,c
Intermediate risk10 (43.5)13 (56.5)0
High risk1 (4.8)4 (19)16 (76.2)
Cellular typeFusiform29 (59.2)11 (22.4)9 (18.4)0.114
Mixed5 (26.3)7 (36.8)7 (36.8)
Epithelioid3 (75)1 (25)0
CellularityAbsent17 (89.5)2 (10.5)0<0.001a,b
Present20 (37.7)17 (32.1)16 (30.2)
Cytologic atypiaAbsent14 (100)00<0.001a,b
Mild19 (48.7)12 (30.8)8 (20.5)
Present4 (21.1)7 (36.8)8 (42.1)
Growth patternInfiltrative7 (70)1 (10)2 (20)0.370
Expansive30 (48.4)18 (29)14 (22.6)
UlcerationAbsent30 (60)11 (22)9 (18)0.088
Present7 (31.8)8 (36.4)7 (31.8)
NecrosisAbsent31 (62)11 (22)8 (16)0.022b
Present6 (27.3)8 (36.4)8 (36.4)
HemorrhageAbsent25 (71.4)7 (20)3 (8.6)0.002a,b
Present12 (32.4)12 (32.4)13 (35.1)
Invasion depthSubmucosal14 (82.4)2 (11.8)1 (5.9)0.007a,b
Muscle layer12 (63.2)4 (21.1)3 (15.8)
Serosal11 (30.6)13 (36.1)12 (33.3)
Tumor size≤5 cm26 (78.8)6 (18.2)1 (3)<0.001a,b
5–10 cm10 (41.7)9 (37.5)5 (20.8)
≥10 cm1 (6.7)4 (26.7)10 (66.7)

Data were shown as n (%) and mean ± standard deviation. Statistically significant p values were shown as bold.

According to pairwise comparisons:

there was statistically significant difference between Ki-67<%1 and Ki-67=%1–%10;

there was statistically significant difference between Ki-67<%1 and Ki-67>%10;

there was statistically significant difference between Ki-67=%1–%10 and Ki-67>%10.

Figure 4

+++ Nuclear staining with Ki-67 in high-risk GISTs (immunoperoxidase ×400).

When we stained the samples for Ki-67, 37 (51.4%) of the cases were below 1%, 19 (26.4%) were between 1% and 10%, and 16 (22.2%) were above 10%. In the L risk group, 26 (93%) of the 28 cases showed <1% staining, and 2 (7%) had 1–5% staining. In the IM risk group, 10 (44%) of the 23 cases showed <1% staining and 13 had 1–10% staining. In the H risk group, only 1 (4.8%) of the 21 cases had <1% staining, whereas 4 had 1–10% staining and 16 showed >10% staining. Correlation coefficients were calculated between the positive results for CD117, MMP-7, nestin, and Ki-67 with the tumor size, localization, grade, cellularity, cytologic atypia, ulceration, necrosis, hemorrhage, and invasion depth. For CD117, the correlations between the groups showed that tumor localization and tumor grade were statistically significant. For the MMP-7 correlations, the tumor grade, cellularity, cytologic atypia, ulceration, necrosis, and tumor size were statistically significant. For the nestin correlations, the tumor grade and tumor size were statistically significant, and for Ki67 all of the variables were significantly correlated (Table 2). When correlations among CD117, MMP-7, nestin, and Ki-67 were examined, nestin and Ki-67 were both significantly correlated with CD117 and MMP-7 (Table 3).
Table 2

Distribution of the correlations between CD-117, MMP-7, nestin, Ki-67, and other parameters.

CD117MMP-7NestinKi-67
rprprprp
Localization0.2840.0160.0890.458−0.0040.9750.3550.002
Grade0.2500.0340.467<0.0010.2910.0130.799<0.001
Cellularity−0.0900.4510.3050.0090.1370.2500.459<0.001
Cytologic atypia0.1300.2780.468<0.0010.0330.7860.510<0.001
Ulceration−0.1810.1290.3570.0020.1500.2080.2500.034
Necrosis−0.0250.8320.411<0.0010.1570.1890.3220.006
Hemorrhage0.0650.5860.1770.1360.2230.0590.410<0.001
Invasion depth0.1090.3620.1090.363−0.1030.3870.430<0.001
Tumor size0.0350.7730.4000.0010.2660.0240.615<0.001

r – Spearman’s correlation coefficients. Statistically significant p values were shown as bold.

Table 3

Distribution of the correlations between CD-117, MMP-7, nestin and Ki-67.

MMP-7NestinKi-67
rprprp
CD1170.1880.1130.2790.0180.3860.001
MMP-70.3220.0060.3560.002
Nestin0.2200.063

r – Spearman’s correlation coefficients. Statistically significant p values were shown as bold.

When the diagnostic performances of the MMP-7 and nestin results relative to CD117 were examined, the sensitivities were 92.98% and 98.25%, respectively, and the specificities were 13.33% and 26.67%. Both methods were strong at determining real positivity and weak at determining real negativity.

Discussion

Gastrointestinal stromal tumors usually remain silent until they reach a large diameter, and the symptoms they present with at that point vary according to the tumor localization and dimension. These tumors usually manifest in conjunction with nonspecific symptoms such as abdominal pain, loss of appetite, nausea, anorexia, weight loss, fever, and obstruction. The patients may also present with life-threatening intraperitoneal hemorrhage as a result of massive bleeding due to a chronic or mucosal ulceration or rupture. In some patients, the mass may be palpable [14,15], and aggressive GISTs may produce metastases in the liver or anywhere in the abdomen [16]. To make an appropriate diagnosis, the GISTs need to be classified, and the prognosis is then determined according to the immunohistochemical and morphological characteristics of the tumor [17,18]. One of the most important properties used to describe GISTs is the expression of the C-kit protein because it is present in most of these tumors, and the immunomarker for C-kit expression is CD117 [19,20]. As expected, we found that 70 of 72 of our cases tested positive for CD117. It has been suggested that MMP-7 is excessively expressed in tissues with tumors and is related to other processes such as apoptosis, invasion, metastasis, and angiogenesis [21]. We found MMP-7 was positively expressed in 71 patients, with only 1 sample testing negative. Furthermore, correlations of MMP-7 with the other groups (nestin, CD117, and Ki 67) showed that the parameters of grade, cellularity, cytological atypia, ulceration, necrosis, and tumor size were statistically significant. However, no significant correlations were found between MMP-7 positivity localization, hemorrhage, or invasion depth. Similarly, in a study by Ding Li et al. [22] that included 68 GIST cases, they determined that the expression of the immunomarkers increased in line with higher Fletcher risk rates, and as a result, MMP-3 and MMP-7 staining increased. Nestin is an intermediate filament involved in the proliferation and development of fetal and embryonic cells. It is also involved in the expression of adult stem and progenitor cell populations, including vascular endothelial, striated muscle, hair follicle precursor, islet precursor, and liver cells. In addition, nestin is reactivated in cases of trauma and other pathological conditions [23-27]. Enache et al. [28] found that 63 of the 81 patients in their study with GISTs tested positive for nestin. We found 70 of our 72 samples stained positive for nestin, with only 3 staining mildly, and 2 moderately. We identified significant correlations between the samples that tested positive for nestin and tumor grade and tumor size, whereas no significant correlations were found between nestin and localization, cellularity, cytologic atypia, growth pattern, ulceration, necrosis, hemorrhage, or invasion depth. With GISTs, the mitotic rate is related to the prognosis. The immunomarker Ki-67 can be used to calculate a proliferation index [29]. In a study involving 113 patients with GISTs, Liu et al. [30] found that 74 (65.5%) tested positive for Ki-67. In our study, we found that 100% of our cases were positive for Ki-67. While significant correlations were found between the samples that tested positive for Ki-67, CD117, and nestin, no significant correlation was identified with MMP-7 positivity. In a study by Fletcher et al. [11], increased Ki-67 proliferation index rates were seen with high-risk GISTs, and we similarly found that these rates became higher as the tumor grade increased. The CD117 positive and negative groups were significantly correlated with those of Ki-67 and nestin, but there were no statistically significant correlations with other patient characteristics. There were also no patient characteristics correlated with the positive and negative MMP-7 groups.

Conclusions

Consistent staining with nestin and MMP-7 showed that these immunomarkers were sensitive to GISTs, regardless of the cell type and tumor grade. Additionally, positive correlations were seen with regard to nestin and MMP-7 and the tumor grade, which suggests that these markers might play an important role in the development of GISTs. Furthermore, Ki-67 should be evaluated as a prognostic factor in association with CD117, since it is used in the diagnosis of these tumors. Our findings also indicate that MMP-7 and nestin may be beneficial markers given their sensitivity to GISTs.
  27 in total

1.  Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases.

Authors:  M Miettinen; M Sarlomo-Rikala; L H Sobin; J Lasota
Journal:  Am J Surg Pathol       Date:  2000-10       Impact factor: 6.394

Review 2.  Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations.

Authors:  Michael C Heinrich; Brian P Rubin; B Jack Longley; Jonathan A Fletcher
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

3.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

4.  Gastrointestinal stromal tumors: a spectrum of disease.

Authors:  Cord Sturgeon; Gregorio Chejfec; N Joseph Espat
Journal:  Surg Oncol       Date:  2003-07       Impact factor: 3.279

Review 5.  Gastrointestinal stromal tumors: biology and treatment.

Authors:  Florence Duffaud; Jean-Yves Blay
Journal:  Oncology       Date:  2003       Impact factor: 2.935

6.  Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach.

Authors:  N A C S Wong; R Young; R D G Malcomson; A G Nayar; L A Jamieson; V E Save; F A Carey; D H Brewster; C Han; A Al-Nafussi
Journal:  Histopathology       Date:  2003-08       Impact factor: 5.087

Review 7.  Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review.

Authors:  Markku Miettinen; Wa'el El-Rifai; Leslie H L Sobin; Jerzy Lasota
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

Review 8.  Biology of gastrointestinal stromal tumors.

Authors:  Christopher L Corless; Jonathan A Fletcher; Michael C Heinrich
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

9.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Authors:  Michael C Heinrich; Christopher L Corless; George D Demetri; Charles D Blanke; Margaret von Mehren; Heikki Joensuu; Laura S McGreevey; Chang-Jie Chen; Annick D Van den Abbeele; Brian J Druker; Beate Kiese; Burton Eisenberg; Peter J Roberts; Samuel Singer; Christopher D M Fletcher; Sandra Silberman; Sasa Dimitrijevic; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544

10.  Nestin expression in hair follicle sheath progenitor cells.

Authors:  Lingna Li; John Mignone; Meng Yang; Maja Matic; Sheldon Penman; Grigori Enikolopov; Robert M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-06       Impact factor: 11.205

View more
  7 in total

1.  Activity of MMP1 and MMP13 and amino acid metabolism in patients with alcoholic liver cirrhosis.

Authors:  Andrzej Prystupa; Maria Szpetnar; Anna Boguszewska-Czubara; Andrzej Grzybowski; Jarosław Sak; Wojciech Załuska
Journal:  Med Sci Monit       Date:  2015-04-07

2.  Effects of siRNA-Mediated Knockdown of HDAC1 on the Biological Behavior of Esophageal Carcinoma Cell Lines.

Authors:  Xing Wang; Haisheng Guo; Weixin Liu; Chunmei Yang; Lei Yang; Dongguan Wang; Xunguo Wang
Journal:  Med Sci Monit       Date:  2016-04-18

Review 3.  Ki67 is a biological marker of malignant risk of gastrointestinal stromal tumors: A systematic review and meta-analysis.

Authors:  Yu Zhou; Wenqing Hu; Ping Chen; Masanobu Abe; Lei Shi; Si-Yuan Tan; Yong Li; Liang Zong
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

4.  Personalized CT-based radiomics nomogram preoperative predicting Ki-67 expression in gastrointestinal stromal tumors: a multicenter development and validation cohort.

Authors:  Qing-Wei Zhang; Yun-Jie Gao; Ran-Ying Zhang; Xiao-Xuan Zhou; Shuang-Li Chen; Yan Zhang; Qiang Liu; Jian-Rong Xu; Zhi-Zheng Ge
Journal:  Clin Transl Med       Date:  2020-01-31

5.  Preoperative prediction of gastrointestinal stromal tumors with high Ki-67 proliferation index based on CT features.

Authors:  Cai-Wei Yang; Xi-Jiao Liu; Lian Zhao; Feng Che; Yuan Yin; Hui-Jiao Chen; Bo Zhang; Min Wu; Bin Song
Journal:  Ann Transl Med       Date:  2021-10

6.  Ki67 for evaluating the prognosis of gastrointestinal stromal tumors: A systematic review and meta-analysis.

Authors:  Ji Li; An-Ran Wang; Xiao-Dong Chen; Hong Pan; Shi-Qiang Li
Journal:  Oncol Lett       Date:  2022-04-27       Impact factor: 3.111

7.  Necl 4 and RNase 5 Are Important Biomarkers for Gastric and Colon Adenocarcinomas.

Authors:  İlyas Sayar; Aysun Gökçe; Levent Demirtas; Hüseyin Eken; Ferda Keskin Çimen; Orhan Çimen
Journal:  Med Sci Monit       Date:  2017-05-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.